Company intelligence / Profile preview

Arrowhead Technologies

Pasadena, California, USarrowheadtechnologies.com ↗

Ownership: Private
Employees: ~400
Development stage: Other

Overview

Arrowhead Pharmaceuticals develops innovative medicines using its proprietary TRiM™ platform to deliver small interfering RNAs that silence disease-causing genes. The company has a broad clinical pipeline targeting cardiometabolic, liver, pulmonary and rare genetic diseases. Several candidates are in mid-to-late-stage clinical trials with promising results reported across multiple indications.

Therapeutic areas: Metabolic DisordersNeurologyPulmonologyInfectious DiseasesGastroenterologyImmunologyCardiovascular
Modalities: RNA interference therapy (RNAi)Small interfering RNA
Industry: Biotech

Partnerships

Amgen – olpasiran program partnershipTakeda – fazirsiran program partnershipGSK – GSK4532990 collaboration

Beyond the preview

Go deeper on Arrowhead Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arrowhead Technologies.

Explore the full profile